Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges

References

• Pal M, Berhanu G, Desalegn C, et al. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020;12(3).
   Web of Science ®Google Scholar
• Flynn Makic MB. Prone position of patients with COVID-19 and acute respiratory distress syndrome. J Perianesth Nurs. 2020;35(4):437–438.
   PubMed Web of Science ®Google Scholar
• Piantadosi CA, Schwartz DA. The acute respiratory distress syndrome. Ann Intern Med. 2004;141(6):460–470.
   PubMed Web of Science ®Google Scholar
• Han J, Li Y, Li Y. Strategies to enhance mesenchymal stem cell-based therapies for acute respiratory distress syndrome. Stem Cells Int. 2019;2019:5432134.
   PubMed Web of Science ®Google Scholar
• Li L, Huang Q, Wang DC, et al. Acute lung injury in patients with COVID-19 infection. Clin Transl Med. 2020;10(1):20–27.
   PubMed Web of Science ®Google Scholar
• Patel VJ, Biswas Roy S, Mehta HJ, et al. Alternative and natural therapies for acute lung injury and acute respiratory distress syndrome. Biomed Res Int. 2018;2018:2476824.
   PubMed Web of Science ®Google Scholar
• Puneet P, Moochhala S, Bhatia M. Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2005;288(1):L3–L15.
   PubMed Web of Science ®Google Scholar
• Rana MM. Cytokine storm in COVID-19: potential therapeutics for immunomodulation. J Res Clin Med. 2020;8(1):38–38.
   Google Scholar
• Hojyo S, Uchida M, Tanaka K, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40(1):37.
   PubMed Web of Science ®Google Scholar
• Beitler JR, Schoenfeld DA, Taylor Thompson B. Preventing ARDS: progress, promise, and pitfalls. Chest. 2014;146(4):1102–1113.
   PubMed Web of Science ®Google Scholar
• Osman N, Kaneko K, Carini V, et al. Saleem, I. Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies. Expert Opin Drug Deliv. 2018;15(8):821–834.
   PubMed Web of Science ®Google Scholar
• Patil JS, Sarasija S. Pulmonary drug delivery strategies: a concise, systematic review. Lung India. 2012;29(1):44–49.
   PubMedGoogle Scholar
• Omri A. Pulmonary drug and vaccine delivery: therapeutic significance and major challenges. Expert Opin Drug Deliv. 2015;12(6):853–855.
   PubMed Web of Science ®Google Scholar
• Song HHG, Rumma RT, Ozaki CK, et al. Vascular tissue engineering: progress, challenges, and clinical promise. Cell Stem Cell. 2018;22(3):340–354.
   PubMed Web of Science ®Google Scholar
• Van Rijt SH, Bein T, Meiners S. Medical nanoparticles for next generation drug delivery to the lungs. Eur Respir J. 2014;44(3):765–774.
   PubMed Web of Science ®Google Scholar
• Din FU, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. IJN. 2017;12:7291–7309.
   Web of Science ®Google Scholar
• Tsuchiya T, Doi R, Obata T, et al. Lung microvascular niche, repair, and engineering. Front Bioeng Biotechnol. 2020;8:105.
   PubMed Web of Science ®Google Scholar
• Lim YH, Tiemann KM, Hunstad DA, et al. Polymeric nanoparticles in development for treatment of pulmonary infectious diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016;8(6):842–871.
   PubMed Web of Science ®Google Scholar
• De Santis MM, Bölükbas DA, Lindstedt S, et al. How to build a lung: latest advances and emerging themes in lung bioengineering. Eur Respir J. 2018;52(1):1–19.
   Web of Science ®Google Scholar
• Hou YJ, Okuda K, Edwards CE, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182(2):429–446.e14.
   PubMed Web of Science ®Google Scholar
• Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590.
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316–329.
   PubMed Web of Science ®Google Scholar
• Badraoui R, Alrashedi MM, El-May MV, et al. Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19. J Biomol Struct Dyn. 2020;1–10.
   Web of Science ®Google Scholar
• Sartori C, Matthay MA. Alveolar epithelial fluid transport in acute lung injury: new insights. Eur Respir J. 2002;20(5):1299–1313.
   PubMed Web of Science ®Google Scholar
• Matuschak GM, Lechner AJ. Acute lung injury and the acute respiratory distress syndrome: pathophysiology and treatment. Mo Med. 2010;107(4):252–258.
   PubMedGoogle Scholar
• Zemans RL, Matthay MA. What drives neutrophils to the alveoli in ARDS? Thorax. 2017;72(1):1–3.
   PubMed Web of Science ®Google Scholar
• Gallelli L, Zhang L, Wang T, et al. Severe acute lung injury related to COVID-19 infection: a review and the possible role for escin. J Clin Pharmacol. 2020;60(7):815–825.
   PubMed Web of Science ®Google Scholar
• Matthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol. 2005;33(4):319–327.
   PubMed Web of Science ®Google Scholar
• Udugama B, Kadhiresan P, Kozlowski HN, et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano. 2020;14(4):3822–3835.
   PubMed Web of Science ®Google Scholar
• Bhalla N, Pan Y, Yang Z, et al. Opportunities and challenges for biosensors and nanoscale analytical tools for pandemics: COVID-19. ACS Nano. 2020;14(7):7783–7807.
   PubMed Web of Science ®Google Scholar
• Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results: hidden problems and costs. Lancet Respir Med. 2020;8(12):1167–1168.(20)30453-7.
   PubMed Web of Science ®Google Scholar
• Pokhrel P, Hu C, Mao H. Detecting the coronavirus (CoVID-19). ACS Sens. 2020;5(8):2283–2297.
   PubMed Web of Science ®Google Scholar
• Malik AA, Nantasenamat C, Piacham T. Molecularly imprinted polymer for human viral pathogen detection. Mater Sci Eng C Mater Biol Appl. 2017;77:1341–1348.
   PubMed Web of Science ®Google Scholar
• Goud KY, Reddy KK, Khorshed A, et al. Electrochemical diagnostics of infectious viral diseases: trends and challenges. Biosens Bioelectron. 2021;180:113112.
   PubMed Web of Science ®Google Scholar
• Navakul K, Warakulwit C, Yenchitsomanus P. t, et al. A novel method for dengue virus detection and antibody screening using a graphene-polymer based electrochemical biosensor. Nanomedicine. 2017;13(2):549–557.
   PubMed Web of Science ®Google Scholar
• Lu CH, Zhang Y, Tang SF, et al. Sensing HIV related protein using epitope imprinted hydrophilic polymer coated quartz crystal microbalance. Biosens Bioelectron. 2012;31(1):439–444.
   PubMed Web of Science ®Google Scholar
• Wangchareansak T, Thitithanyanont A, Chuakheaw D, et al. A novel approach to identify molecular binding to the influenza virus H5N1: screening using molecularly imprinted polymers (MIPs). Medchemcomm. 2014;5(5):617–621.
   Web of Science ®Google Scholar
• Tai DF, Lin CY, Wu TZ, et al. Recognition of dengue virus protein using epitope-mediated molecularly imprinted film. Anal Chem. 2005;77(16):5140–5143.
   PubMed Web of Science ®Google Scholar
• Nandy Chatterjee T, Bandyopadhyay R. A molecularly imprinted polymer-based technology for rapid testing of COVID-19. Trans Indian Natl Acad Eng. 2020;5(2):225–228.
   Google Scholar
• Iravani S. Nano- and biosensors for the detection of SARS-CoV-2: challenges and opportunities. Mater Adv. 2020;1(9):3092–3103.
   Google Scholar
• Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA. 2020;323(15):1499–1500.
   PubMed Web of Science ®Google Scholar
• Papazian L, Aubron C, Brochard L, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1):1–18.
   Google Scholar
• Aokage T, Palmér K, Ichiba S, et al. Extracorporeal membrane oxygenation for acute respiratory distress syndrome. J Intensive Care. 2015;3(1):17.
   PubMedGoogle Scholar
• Wu MY, Huang CC, Wu TI, et al. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome in adults prognostic factors for outcomes. Medicine (United States). 2016;95(8):e2870.
   Google Scholar
• Wu R, Wang L, Kuo HCD, et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Reports. 2020;6:56–70.
   PubMedGoogle Scholar
• Ho ATN, Patolia S, Guervilly C. Neuromuscular blockade in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. J Intensive Care. 2020;8:1–11. https://doi.org/10.1186/s40560-020-0431-z.
   PubMed Web of Science ®Google Scholar
• Russell B, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19 - a systematic review of current evidence. Ecancermedicalscience. 2020;14(1022): 1–43.
   Google Scholar
• Curran CS, Rivera DR, Kopp JB. COVID-19 usurps host regulatory networks. Front Pharmacol. 2020;11:1278.
   PubMed Web of Science ®Google Scholar
• Bonam SR, Kaveri SV, Sakuntabhai A, et al. Adjunct immunotherapies for the management of severely ill COVID-19 patients. Cell Rep Med. 2020;1(2):100016.
   PubMedGoogle Scholar
• Sivasankarapillai VS, Pillai AM, Rahdar A, et al. On facing the SARS-CoV-2 (COVID-19) with combination of nanomaterials and medicine: possible strategies and first challenges. Nanomaterials. 2020;10(5):852.
   Web of Science ®Google Scholar
• Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-NCoV lung injury. Lancet. 2020;395(10223):473–475.
   PubMed Web of Science ®Google Scholar
• Chakravarty M, Vora A. Nanotechnology-based antiviral therapeutics. Drug Deliv Transl Res. 2020;1–40.
   PubMed Web of Science ®Google Scholar
• Patel A, Patel M, Yang X, et al. Recent advances in protein and peptide drug delivery: a special emphasis on polymeric nanoparticles. Protein Pept Lett. 2014;21(11):1102–1120.
   PubMed Web of Science ®Google Scholar
• Casalini T, Rossi F, Castrovinci A, et al. A perspective on polylactic acid-based polymers use for nanoparticles synthesis and applications. Front Bioeng Biotechnol. 2019;7:259.
   PubMed Web of Science ®Google Scholar
• Daglar B, Ozgur E, Corman ME, et al. Polymeric nanocarriers for expected nanomedicine: current challenges and future prospects. RSC Adv. 2014;4(89):48639–48659.
   Web of Science ®Google Scholar
• Avramović N, Mandić B, Savić-Radojević A, et al. Polymeric nanocarriers of drug delivery systems in cancer therapy. Pharmaceutics. 2020;12(4):298.
   PubMed Web of Science ®Google Scholar
• Zhao J, Stenzel MH. Entry of nanoparticles into cells: the importance of nanoparticle properties. Polym Chem. 2018;9(3):259–272.
   Web of Science ®Google Scholar
• Vijayakameswara Rao N, Ko H, Lee J, et al. Recent progress and advances in stimuli-responsive polymers for cancer therapy. Front Bioeng Biotechnol. 2018;6:110.
   PubMedGoogle Scholar
• Brighenti R, Li Y, Vernerey FJ. Smart polymers for advanced applications: a mechanical perspective review. Front Mater. 2020;7:196.
   Web of Science ®Google Scholar
• Mohd Amin MCI, Ahmad N, Halib N, et al. Synthesis and characterization of thermo- and PH-responsive bacterial cellulose/acrylic acid hydrogels for drug delivery. Carbohydr Polym. 2012;88(2):465–473.
   Web of Science ®Google Scholar
• De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695–747.
   PubMed Web of Science ®Google Scholar
• Soota K, Maliakkal B. Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection. World J Gastroenterol. 2014;20(43):16184–16190.
   PubMed Web of Science ®Google Scholar
• Li C, Wang J, Wang Y, et al. Recent progress in drug delivery. Acta Pharm Sin B. 2019;9(6):1145–1162.
   PubMed Web of Science ®Google Scholar
• Haggag Y, Elshikh M, El-Tanani M, et al. Nanoencapsulation of sophorolipids in PEGylated poly(lactide-co-glycolide) as a novel approach to target colon carcinoma in the murine model. Drug Deliv Transl Res. 2020;10(5):1353–1366.
   PubMed Web of Science ®Google Scholar
• Hillaireau H, Le Doan T, Besnard M, et al. Encapsulation of antiviral nucleotide analogues azidothymidine-triphosphate and cidofovir in poly(iso-butylcyanoacrylate) nanocapsules. Int J Pharm. 2006;324(1):37–42.
   PubMedGoogle Scholar
• Deng S, Gigliobianco MR, Censi R, et al. Polymeric nanocapsules as nanotechnological alternative for drug delivery system: current status, challenges and opportunities. Nanomaterials. 2020;10(5):847.
   Web of Science ®Google Scholar
• Donalisio M, Leone F, Civra A, et al. Acyclovir-loaded chitosan nanospheres from nano-emulsion templating for the topical treatment of herpesviruses infections. Pharmaceutics. 2018;10(2):46.
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu H, Song L. Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review. J Nanobiotechnology. 2020;18(1):145.
   PubMed Web of Science ®Google Scholar
• Nishiyama N, Matsumura Y, Kataoka K. Development of polymeric micelles for targeting intractable cancers. Cancer Sci. 2016;107(7):867–874.
   PubMed Web of Science ®Google Scholar
• Suk JS, Xu Q, Kim N, et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28–51.
   PubMed Web of Science ®Google Scholar
• Wu J, Yuan J, Ye B, et al. Dual-responsive core crosslinking glycopolymer-drug conjugates nanoparticles for precise hepatocarcinoma therapy. Front Pharmacol. 2018;9(Jul):663.
   PubMedGoogle Scholar
• Kim K-T, Lee J-Y, Kim D-D, et al. Recent progress in the development of poly(lactic-co-glycolic acid)-based nanostructures for cancer imaging and therapy. Pharmaceutics. 2019;11(6):280.
   Web of Science ®Google Scholar
• Li W, Yu F, Wang Q, et al. Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy. AIDS. 2016;30(6):827–837.
   PubMed Web of Science ®Google Scholar
• Lu X, Zhu T, Chen C, et al. Right or left: the role of nanoparticles in pulmonary diseases. Int J Mol Sci. 2014;15(10):17577–17600.
   PubMed Web of Science ®Google Scholar
• Jamali A, Mottaghitalab F, Abdoli A, et al. Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by SiRNA. Drug Deliv Transl Res. 2018;8(1):12–20.
   PubMed Web of Science ®Google Scholar
• Kudgus RA, Walden CA, McGovern RM, et al. Tuning pharmacokinetics and biodistribution of a targeted drug delivery system through incorporation of a passive targeting component. Sci Rep. 2014;4(1):1–9.
   Google Scholar
• Jhaveri AM, Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and SiRNA. Front Pharmacol. 2014;5:77.
   PubMed Web of Science ®Google Scholar
• Rad AH, Asiaee F, Jafari S, et al. Poly(ethylene glycol)-poly(ε-caprolactone)-based micelles for solubilization and tumor-targeted delivery of silibinin. Bioimpacts. 2020;10(2):87–95.
   PubMed Web of Science ®Google Scholar
• Rani S, Gothwal A, Khan I, et al. Smartly engineered PEGylated Di-block nanopolymeric micelles: duo delivery of isoniazid and rifampicin against mycobacterium tuberculosis. AAPS PharmSciTech. 2018;19(7):3237–3248.
   PubMed Web of Science ®Google Scholar
• Sheth U, Tiwari S, Bahadur A. Preparation and characterization of anti-tubercular drugs encapsulated in polymer micelles. J Drug Deliv Sci Technol. 2018;48:422–428.
   Web of Science ®Google Scholar
• Ahn YS, Baik HJ, Lee BR, et al. Preparation of multifunctional polymeric micelles for antiviral treatment. Macromol Res. 2010;18(8):747–752.
   Web of Science ®Google Scholar
• Alven S, Nqoro X, Buyana B, et al. Polymer-drug conjugate, a potential therapeutic to combat breast and lung cancer. Pharmaceutics. 2020;12(5):406.
   Web of Science ®Google Scholar
• Aquino RS, Park PW. Glycosaminoglycans and infection. Front Biosci (Landmark Ed). 2016;21(6):1260–1277.
   PubMedGoogle Scholar
• Smith AAA, Kryger MBL, Wohl BM, et al. Macromolecular (pro)drugs in antiviral research. Polym Chem. 2014;5(22):6407–6425.
   Web of Science ®Google Scholar
• Van Dongen MA, Dougherty CA, Banaszak Holl MM. Multivalent polymers for drug delivery and imaging: the challenges of conjugation. Biomacromolecules. 2014;15(9):3215–3234.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Lin PI, Wang CC. Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles. Nanomedicine (Lond). 2011;6(6):1011–1026.
   PubMed Web of Science ®Google Scholar
• Dhoke DM, Basaiyye SS, Khedekar PB. Development and characterization of L-HSA conjugated PLGA nanoparticle for hepatocyte targeted delivery of antiviral drug. J Drug Deliv Sci Technol. 2018;47:77–94.
   Web of Science ®Google Scholar
• Destache CJ, Belgum T, Christensen K, et al. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis. 2009;9(198): 1–8.
   PubMedGoogle Scholar
• Ramana LN, Sharma S, Sethuraman S, et al. Evaluation of chitosan nanoformulations as potent anti-HIV therapeutic systems. Biochim Biophys Acta. 2014;1840(1):476–484.
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Pandey R, Sharma S, et al. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci. 2006;48(3):171–176.
   PubMedGoogle Scholar
• Kalombo L, Lemmer Y, Semete-Makokotlela B, et al. Spray-dried, nanoencapsulated, multi-drug anti-tuberculosis therapy aimed at once weekly administration for the duration of treatment. Nanomaterials. 2019;9(8):1167.
   Web of Science ®Google Scholar
• Grande F, Ioele G, Occhiuzzi MA, et al. Reverse transcriptase inhibitors nanosystems designed for drug stability and controlled delivery. Pharmaceutics. 2019;11(5):197.
   PubMed Web of Science ®Google Scholar
• Gong Y, Chowdhury P, Midde NM, et al. Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages. Biochem Biophys Rep. 2017;12:214–219.
   PubMedGoogle Scholar
• Varshosaz J, Taymouri S, Jafari E, et al. Formulation and characterization of cellulose acetate butyrate nanoparticles loaded with nevirapine for HIV treatment. J Drug Deliv Sci Technol. 2018;48:9–20.
   Web of Science ®Google Scholar
• Tyagi R, Lala S, Verma AK, et al. Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. J Drug Target. 2005;13(3):161–171.
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhang P, Chen Z, et al. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral Candida Albicans. Int J Nanomedicine. 2017;12:4269–4283.
   PubMed Web of Science ®Google Scholar
• Giannavola C, Bucolo C, Maltese A, et al. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res. 2003;20(4):584–590. [12739765]
   PubMed Web of Science ®Google Scholar
• Fresta M, Fontana G, Bucolo C, et al. Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)‐coated polyethyl‐2‐cyanoacrylate nanosphere‐encapsulated acyclovir. J Pharm Sci. 2001;90(3):288–297.
   PubMed Web of Science ®Google Scholar
• Mosqueira VCF, Loiseau PM, Bories C, et al. Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in plasmodium berghei-infected mice. Antimicrob Agents Chemother. 2004;48(4):1222–1228.
   PubMed Web of Science ®Google Scholar
• Calvo P, Vila-Jato JL, Alonso M. J. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci. 1996;85(5):530–536.
   PubMed Web of Science ®Google Scholar
• Li Q, Du YZ, Yuan H, et al. Synthesis of lamivudine stearate and antiviral activity of stearic acid-g-chitosan oligosaccharide polymeric micelles delivery system. Eur J Pharm Sci. 2010;41(3–4):498–507.
   PubMed Web of Science ®Google Scholar
• Silva M, Ricelli NL, Seoud OE, et al. Potential tuberculostatic agent: micelle-forming pyrazinamide prodrug. Arch Pharm (Weinheim). 2006;339(6):283–290.
   PubMed Web of Science ®Google Scholar
• Sawdon AJ, Peng CA. Polymeric micelles for acyclovir drug delivery. Colloids Surf B Biointerfaces. 2014;122:738–745.
   PubMed Web of Science ®Google Scholar
• Yandrapu SK, Kanujia P, Chalasani KB, et al. Development and optimization of thiolated dendrimer as a viable mucoadhesive excipient for the controlled drug delivery: an acyclovir model formulation. Nanomedicine. 2013;9(4):514–522.
   PubMed Web of Science ®Google Scholar
• Ma M, Cheng Y, Xu Z, et al. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur J Med Chem. 2007;42(1):93–98.
   PubMed Web of Science ®Google Scholar
• Bhadra D, Bhadra S, Jain NK. PEGylated peptide dendrimeric carriers for the delivery of antimalarial drug chloroquine phosphate. Pharm Res. 2006;23(3):623–633.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Qu H, Ma M, et al. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study. Eur J Med Chem. 2007;42(7):1032–1038.
   PubMed Web of Science ®Google Scholar
• Cojocaru FD, Botezat D, Gardikiotis I, et al. Nanomaterials designed for antiviral drug delivery transport across biological barriers. Pharmaceutics. 2020;12(2):171.
   PubMed Web of Science ®Google Scholar
• Srinivas P, Reddy A. Formulation and evaluation of isoniazid loaded nanosponges for topical delivery. PNT. 2015;3(1):68–76.
   Google Scholar
• Mcdonald TO, Giardiello M, Martin P, et al. Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. Adv Healthc Mater. 2014;3(3):400–411.
   PubMed Web of Science ®Google Scholar
• Sun B, Yeo Y. Nanocrystals for the parenteral delivery of poorly water-soluble drugs. Curr Opin Solid State Mater Sci. 2012;16(6):295–301.
   PubMed Web of Science ®Google Scholar
• Janaszewska A, Lazniewska J, Trzepiński P, et al. Cytotoxicity of dendrimers. Biomolecules. 2019;9(8):1–23.
   Web of Science ®Google Scholar
• Mhlwatika Z, Aderibigbe BA. Application of dendrimers for the treatment of infectious diseases. Molecules. 2018;23(9):2205.
   Web of Science ®Google Scholar
• Sepúlveda-Crespo D, Ceña-Díez R, Jiménez JL, et al. Mechanistic studies of viral entry: an overview of dendrimer-based microbicides as entry inhibitors against both HIV and HSV-2 overlapped infections. Med Res Rev. 2017;37(1):149–179.
   PubMed Web of Science ®Google Scholar
• Caminade AM, Turrin CO, Majoral JP. Biological properties of phosphorus dendrimers. New J Chem. 2010;34(8):1512–1524.
   Web of Science ®Google Scholar
• Briz V, Sepúlveda-Crespo D, Diniz AR, et al. Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides. Nanoscale. 2015;7(35):14669–14683.
   PubMed Web of Science ®Google Scholar
• Heinrich MA, Martina B, Prakash J. Nanomedicine strategies to target coronavirus. Nano Today. 2020;35:100961.
   PubMed Web of Science ®Google Scholar
• Sun Y, Guo F, Zou Z, et al. Cationic nanoparticles directly bind angiotensin-converting enzyme 2 and induce acute lung injury in mice. Part Fibre Toxicol. 2015;12(1):1–13.
   PubMedGoogle Scholar
• Tan GT, Wickramasinghe A, Verma S, et al. Sulfonic acid polymers are potent inhibitors of HIV-1 induced cytopathogenicity and the reverse transcriptases of both HIV-1 and HIV-2. BBA - Mol. Basis Dis. 1993;1181(2):183–188.
   PubMedGoogle Scholar
• Schols D, De Clercq E, Balzarini J, et al. Sulphated polymers are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, respiratory syncytial virus, and toga-, arena- and retroviruses. Antivir Chem Chemother. 1990;1(4):233–240.
   Web of Science ®Google Scholar
• Danial M, Andersen AHF, Zuwala K, et al. Triple activity of lamivudine releasing sulfonated polymers against HIV-1. Mol Pharm. 2016;13(7):2397–2410.
   PubMedGoogle Scholar
• Bianculli RH, Mase JD, Schulz MD. Antiviral polymers: past approaches and future possibilities. Macromolecules. 2020;53(21):9158–9186.
   Web of Science ®Google Scholar
• Caló E, Khutoryanskiy VV. Biomedical applications of hydrogels: a review of patents and commercial products. Eur Polym J. 2015;65:252–267.
   Web of Science ®Google Scholar
• Zubik K, Singhsa P, Wang Y, et al. Thermo-responsive poly(n-isopropylacrylamide)-cellulose nanocrystals hybrid hydrogels for wound dressing. Polymers (Basel). 2017;9(12):119.
   Google Scholar
• Tian S, Liu G, Wang X, et al. PH-responsive tumor-targetable theranostic nanovectors based on core crosslinked (CCL) micelles with fluorescence and magnetic resonance (MR) dual imaging modalities and drug delivery performance. Polymers (Basel). 2016;8(6):226.
   Web of Science ®Google Scholar
• Ghaeini-Hesaroeiye S, Razmi Bagtash H, Boddohi S, et al. Thermoresponsive nanogels based on different polymeric moieties for biomedical applications. Gels. 2020;6(3):20.
   Web of Science ®Google Scholar
• Chen J, Li G, Liu Q, et al. A photocleavable amphiphilic prodrug self-assembled nanoparticles with effective anticancer activity in vitro. Nanomaterials. 2019;9(6):860.
   Web of Science ®Google Scholar
• Shin JM, Choi GH, Song SH, et al. Metal-phenolic network-coated hyaluronic acid nanoparticles for PH-responsive drug delivery. Pharmaceutics. 2019;11(12):636.
   Web of Science ®Google Scholar
• Gandhi A, Paul A, Sen SO, et al. Studies on thermoresponsive polymers: phase behaviour, drug delivery and biomedical applications. Asian J Pharm Sci. 2015;10(2):99–107.
   Web of Science ®Google Scholar
• Ramos J, Imaz A, Forcada J. Temperature-sensitive nanogels: poly(n-vinylcaprolactam) versus poly(n-isopropylacrylamide). Polym Chem. 2012;3(4):852–856.
   Web of Science ®Google Scholar
• Zhang Q, Honko A, Zhou J, et al. Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett. 2020;20(7):5570–5574.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509–517.
   PubMed Web of Science ®Google Scholar
• Liu MA. The immunologist's grail: vaccines that generate cellular immunity. Proc Natl Acad Sci U S A. 1997;94(20):10496–10498.
   PubMed Web of Science ®Google Scholar
• Tahamtan A, Charostad J, Hoseini Shokouh SJ, et al. An overview of history, evolution, and manufacturing of various generations of vaccines. J Arch Mil Med. 2017;5(e12315 ):1–7.
   Google Scholar
• Finco O, Rappuoli R. Designing vaccines for the twenty-first century society. Front Immunol. 2014;5(Jan):12.
   PubMedGoogle Scholar
• Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Sig Transduct Target Ther. 2020;5:237.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang W, Chen Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586(7830):572–577.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 NCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450.
   PubMed Web of Science ®Google Scholar
• de Alwis R, Gan ES, Chen S, et al. A single dose of self-transcribing and replicating RNA based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.   Mol Ther. 2021 (In Press). doi: https://doi.org/10.1016/j.ymthe.2021.04.001.
   Google Scholar
• Chandra Baray J, Maksudur Rahman Khan M, Mahmud A, et al. BANCOVID, the first D614G variant MRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response. bioRxiv. 2020.
   Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An MRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med. 2020;383:1920–1931.
   PubMed Web of Science ®Google Scholar
• Rauch S, Roth N, Schwendt K, et al. mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents. bioRxiv. 2020. doi: https://doi.org/10.1101/2020.10.23.351775
   Google Scholar
• Shao L, Wu WS. Gene-delivery systems for IPS cell generation. Expert Opin Biol Ther. 2010;10(2):231–242.
   PubMed Web of Science ®Google Scholar
• Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015;35(2):191.
   PubMed Web of Science ®Google Scholar
• Mahalingam S, Ng WH, Liu X. Development of vaccines for SARS-CoV-2. F1000Res. 2020;9:991.
   Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an RAd26 and RAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–897.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Le Gars M, Shukarev G, Heerwegh, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S covid-19 vaccine. N Engl J Med. 2021.
   PubMed Web of Science ®Google Scholar
• Anywaine Z, Whitworth H, Kaleebu P, et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-filo ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. J Infect Dis. 2019;220(1):46–56.
   PubMed Web of Science ®Google Scholar
• Guebre-Xabier M, Patel N, Tian J-H, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020;38(50):7892–7896.
   PubMed Web of Science ®Google Scholar
• Zimmer C, Corum J, Wee S-L. Covid-19 vaccine tracker updates: the latest. The New York Times [accessed Mar 9, 2021]. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html.
   Google Scholar
• Pandey SC, Pande V, Sati D, et al. Vaccination strategies to combat novel corona virus SARS-CoV-2. Life Sci. 2020;256:117956.
   PubMed Web of Science ®Google Scholar
• Brisse M, Vrba SM, Kirk N, et al. Emerging concepts and technologies in vaccine development. Front Immunol. 2020;11:583077.
   PubMed Web of Science ®Google Scholar
• Li J, Xue S, Mao ZW. Nanoparticle delivery systems for SiRNA-based therapeutics. J Mater Chem B. 2016;4(41):6620–6639.
   PubMed Web of Science ®Google Scholar
• Kalam MA, Khan AA, Alshamsan A. Non-invasive administration of biodegradable nano-carrier vaccines. Am J Transl Res. 2017;9(1):15–35.
   PubMed Web of Science ®Google Scholar
• Chauhan G, Madou MJ, Kalra S, et al. Nanotechnology for COVID-19: therapeutics and vaccine research. ACS Nano. 2020;14(7):7760–7782.
   PubMed Web of Science ®Google Scholar
• Ghitman J, Biru EI, Stan R, et al. Review of hybrid PLGA nanoparticles: future of smart drug delivery and theranostics medicine. Mater Des. 2020;193:108805.
   Web of Science ®Google Scholar
• Catoira MC, Fusaro L, Di Francesco D, et al. Overview of natural hydrogels for regenerative medicine applications. J Mater Sci Mater Med. 2019;30(10):1–10.
   Web of Science ®Google Scholar
• Afewerki S, Sheikhi A, Kannan S, et al. Gelatin-polysaccharide composite scaffolds for 3D cell culture and tissue engineering: towards natural therapeutics. Bioeng Transl Med. 2019;4(1):96–115.
   PubMed Web of Science ®Google Scholar
• Galloway AL, Murphy A, DeSimone JM, et al. Development of a nanoparticle-based influenza vaccine using the PRINT technology. Nanomedicine. 2013;9(4):523–531.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al. MRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.
   PubMed Web of Science ®Google Scholar
• Lambricht L, Lopes A, Kos S, et al. Clinical potential of electroporation for gene therapy and DNA vaccine delivery. Expert Opin Drug Deliv. 2016;13(2):295–310.
   PubMed Web of Science ®Google Scholar
• Zhu M, Wang R, Nie G. Applications of nanomaterials as vaccine adjuvants. Hum Vaccin Immunother. 2014;10(9):2761–2774.
   PubMed Web of Science ®Google Scholar
• Bonam SR, Kotla NG, Bohara RA, et al. Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano Today. 2021;36:101051.
   PubMed Web of Science ®Google Scholar
• Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020;288:198114.
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320–2332.
   PubMed Web of Science ®Google Scholar
• Irvine DJ, Hanson MC, Rakhra K, et al. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev. 2015;115(19):11109–11146.
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Dupuis L, Deville S, et al. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines. 2002;1(1):111–118.
   PubMedGoogle Scholar
• Chang JCC, Diveley JP, Savary JR, et al. Adjuvant activity of incomplete freund’s adjuvant. Adv Drug Deliv Rev. 1998;32(3):173–186.
   PubMed Web of Science ®Google Scholar
• Newman MJ, Balusubramanian M, Todd CW. Development of adjuvant-active nonionic block copolymers. Adv Drug Deliv Rev. 1998;32(3):199–223.
   PubMed Web of Science ®Google Scholar
• Huang MH, Huang CY, Lien SP, et al. Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant. Pharm Res. 2009;26(8):1856–1862.
   PubMed Web of Science ®Google Scholar
• Haun BK, Lai C-Y, Williams CA, et al. CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 spike S1 immunization. Front Immunol. 2020;11:599587.
   PubMed Web of Science ®Google Scholar
• Kusi KA, Remarque EJ, Riasat V, et al. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques. Malar J. 2011;10(1):182.
   PubMedGoogle Scholar
• Lakhan N, Stevens NE, Diener KR, et al. CoVaccine HTTM adjuvant is superior to Freund’s adjuvants in eliciting antibodies against the endogenous alarmin HMGB1. J Immunol Methods. 2016;439:37–43.
   PubMed Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J Infect. 2020;80(6):607–613.
   PubMed Web of Science ®Google Scholar
• Nikolova MP, Chavali MS. Recent advances in biomaterials for 3D scaffolds: a review. Bioact Mater. 2019;4:271–292.
   PubMed Web of Science ®Google Scholar
• Wu Z, Kong B, Liu R, et al. Engineering of corneal tissue through an aligned PVA/collagen composite nanofibrous electrospun scaffold. Nanomaterials. 2018;8(2):124.
   Web of Science ®Google Scholar
• Zhang Y, Wang C, Fu L, et al. Fabrication and application of novel porous scaffold in situ-loaded graphene oxide and osteogenic peptide by cryogenic 3D printing for repairing critical-sized bone defect. Molecules. 2019;24(9):1–20.
   Web of Science ®Google Scholar
• Wang L, Dong S, Liu Y, et al. Fabrication of injectable, porous hyaluronic acid hydrogel based on an in-situ bubble-forming hydrogel entrapment process. Polymers (Basel). 2020;12(5):1–15.
   Web of Science ®Google Scholar
• Andrade CF, Wong AP, Waddell TK, et al. Cell-based tissue engineering for lung regeneration. Am J Physiol - Lung Cell Mol Physiol. 2007;292(2):L510–L518.
   PubMed Web of Science ®Google Scholar
• Shannon JM, McCormick-Shannon K, Burhans MS, et al. Chondroitin sulfate proteoglycans are required for lung growth and morphogenesis in vitro. Am J Physiol Cell Mol Physiol. 2003;285(6):L1323–L1336.
   PubMed Web of Science ®Google Scholar
• Guo B, Ma PX. Synthetic biodegradable functional polymers for tissue engineering: a brief review. Sci China Chem. 2014;57(4):490–500.
   PubMed Web of Science ®Google Scholar
• Mohammadi Nasr S, Rabiee N, Hajebi S, et al. Biodegradable nanopolymers in cardiac tissue engineering: from concept towards nanomedicine. Int J Nanomed. 2020;15:4205–4224.
   PubMed Web of Science ®Google Scholar
• Zhu J, Marchant RE. Design properties of hydrogel tissue-engineering scaffolds. Expert Rev Med Devices. 2011;8(5):607–626.
   PubMed Web of Science ®Google Scholar
• Tebyanian H, Karami A, Nourani MR, et al. Lung tissue engineering: an update. J Cell Physiol. 2019;234(11):19256–19270.
   PubMed Web of Science ®Google Scholar
• Shigemura N, Okumura M, Mizuno S, et al. Lung tissue engineering technique with adipose stromal cells improves surgical outcome for pulmonary emphysema. Am J Respir Crit Care Med. 2006;174(11):1199–1205.
   PubMed Web of Science ®Google Scholar
• Deng M, Gu Y, Liu Z, et al. Endothelial differentiation of human adipose-derived stem cells on polyglycolic acid/polylactic acid mesh. Stem Cells Int. 2015;2015:1–11.
   Web of Science ®Google Scholar
• Pappalardo D, Mathisen T, Finne-Wistrand A. Biocompatibility of resorbable polymers: a historical perspective and framework for the future. Biomacromolecules. 2019;20(4):1465–1477.
   PubMed Web of Science ®Google Scholar
• Yang R, Tan L, Cen L, et al. An injectable scaffold based on crosslinked hyaluronic acid gel for tissue regeneration. RSC Adv. 2016;6(20):16838–16850.
   Web of Science ®Google Scholar
• George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75(11):1009–1016.
   PubMed Web of Science ®Google Scholar
• Sadikot RT, Kolanjiyil AV, Kleinstreuer C, et al. Nanomedicine for treatment of acute lung injury and acute respiratory distress syndrome. Biomed Hub. 2017;2(2):1–12.
   PubMedGoogle Scholar
• Sadikot RT. Peptide nanomedicines for treatment of acute lung injury. In Methods in enzymology. Vol. 508. Academic Press Inc.; 2012, 508:315–324.
   Google Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71.
   PubMed Web of Science ®Google Scholar
• Weiss C, Carriere M, Fusco L, et al. Toward nanotechnology-enabled approaches against the COVID-19 pandemic. ACS Nano. 2020;14(6):6383–6406.
   PubMed Web of Science ®Google Scholar
• Santos I, de A, Grosche VR, Bergamini FRG, et al. Antivirals against coronaviruses: candidate drugs for SARS-CoV-2 treatment? Front Microbiol. 2020;11:1818.
   PubMed Web of Science ®Google Scholar
• Itani R, Tobaiqy M, Faraj A. Al. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics. 2020;10(13):5932–5942.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hardie J, Zhang X, et al. Effects of engineered nanoparticles on the innate immune system. Semin Immunol. 2017;34:25–32.
   PubMed Web of Science ®Google Scholar
• Richtering W, Alberg I, Zentel R. Nanoparticles in the biological context: surface morphology and protein corona formation. Small. 2020;16(39):2002162.
   PubMed Web of Science ®Google Scholar
• Wolfram J, Zhu M, Yang Y, et al. Safety of nanoparticles in medicine. CDT. 2015;16(14):1671–1681.
   Google Scholar
• Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat. Rev. Mater. 2016;1:16071.
   PubMed Web of Science ®Google Scholar
• Ashammakhi N, Ahadian S, Xu C, et al. Bioinks and bioprinting technologies to make heterogeneous and biomimetic tissue constructs. Mater Today Bio. 2019;1:100008.
   PubMedGoogle Scholar
• Annabi N, Nichol JW, Zhong X, et al. Controlling the porosity and microarchitecture of hydrogels for tissue engineering. Tissue Eng Part B Rev. 2010;16(4):371–383. [InsertedFromOnline[pubmedMismatch]]
   PubMed Web of Science ®Google Scholar